Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia (OligoTreat)
2022-000054-28Phase 2Active
- Sponsor
- LMU Klinikum
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of clemastine in schizophrenia, sponsored by LMU Klinikum. Primary endpoints: Working memory performance (n-back 2-back, d-prime) and Global Assessment of Functioning (GAF). Started Jan 2023; status: active.
02
Drugs
clemastine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2022-000054-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000054-28.